Lisata Therapeutics (LSTA) Stock Overview
A clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
LSTA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lisata Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.97 |
| 52 Week High | US$4.20 |
| 52 Week Low | US$1.81 |
| Beta | 1.09 |
| 1 Month Change | -4.37% |
| 3 Month Change | -22.13% |
| 1 Year Change | -34.77% |
| 3 Year Change | -22.13% |
| 5 Year Change | -90.82% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?
Aug 13
We Think Lisata Therapeutics (NASDAQ:LSTA) Needs To Drive Business Growth Carefully
Apr 26
Certepetide Advancements And Regulatory Approvals Will Set New Care Standards
Advancements in certepetide and regulatory achievements could expedite market entry, fostering revenue growth and enhancing treatment standards.Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation
Dec 24Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation
Jul 15Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?
Mar 22We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
Sep 15Caladrius rallies on approval of merger, name change to Lisata Therapeutics
Sep 14Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01
Aug 04We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
May 02We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate
Jan 05Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth
May 09Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation
Nov 30
Shareholder Returns
| LSTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.4% | 1.1% | 1.3% |
| 1Y | -34.8% | 26.4% | 15.8% |
Return vs Industry: LSTA underperformed the US Biotechs industry which returned 26.4% over the past year.
Return vs Market: LSTA underperformed the US Market which returned 15.8% over the past year.
Price Volatility
| LSTA volatility | |
|---|---|
| LSTA Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: LSTA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LSTA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 26 | Dave Mazzo | www.lisata.com |
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Lisata Therapeutics, Inc. Fundamentals Summary
| LSTA fundamental statistics | |
|---|---|
| Market cap | US$17.38m |
| Earnings (TTM) | -US$18.24m |
| Revenue (TTM) | US$1.07m |
Is LSTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LSTA income statement (TTM) | |
|---|---|
| Revenue | US$1.07m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.07m |
| Other Expenses | US$19.31m |
| Earnings | -US$18.24m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.07 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,704.86% |
| Debt/Equity Ratio | 0% |
How did LSTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/28 14:53 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lisata Therapeutics, Inc. is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jan Wald | Benchmark Company |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kumaraguru Raja | Brookline Capital Markets |